United States

People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

22 Mar 2019
Change (% chg)

$-0.73 (-6.55%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Ray, Debanjan 

Mr. Debanjan Ray has been appointed as chief financial officer and head of corporate development since May 2017. Mr. Ray served as our senior vice president of corporate development & strategy from August 2015 to May 2017 and previously as our vice president of business development and alliance management from August 2011 to August 2015. Prior to joining CytomX, he served as vice president of business development at Itero Biopharmaceuticals, Inc. from May 2008 to August 2011. Mr. Ray was associate director, business development at Portola Pharmaceuticals from January 2006 to May 2008. Prior to that, Mr. Ray was an associate in the life sciences venture practice at J.P. Morgan Partners and a business analyst in the healthcare practice at McKinsey & Company. Mr. Ray holds an MBA from The Wharton School, University of Pennsylvania and received his B.S. degree in chemical engineering and biology from the Massachusetts Institute of Technology.

Basic Compensation

Total Annual Compensation, USD 351,126
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,212,000
Fiscal Year Total, USD 1,563,120

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Sean McCarthy


Debanjan Ray


Nick Galli


Leslie Robbins


W. Michael Kavanaugh


Rachel Humphrey

As Of  30 Dec 2017